0
Deep & Emerging Tech·September 5, 2026·1 min read

Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.

Share

The payoff from long‑horizon ‘impossible’ oncology bets is a reminder that real biotech value often comes from decade‑scale conviction, not quarterly milestones. Operators in adjacent fields — including AI‑driven drug discovery — should calibrate investor conversations around timelines that match the biology, not the hype cycle.